Nuclear Medicine Therapeutics Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Type (Alpha Emitters, Beta Emitters, and Brachytherapy), by Application (Oncology, Cardiology, Thyroid, and Other Applications), By Region, and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 985.80 million

CAGR (2024-2028)

9.60%

Fastest Growing Segment

Oncology 

Largest Market

North America

 

Market Overview

Global Nuclear Medicine Therapeutics Market has valued at USD 985.80 million in 2022 and is anticipated to switness an impressive growth in the forecast period with a CAGR of 9.60% through 2028. Nuclear medicine therapeutics, also known as radiotherapy or radionuclide therapy, is a branch of nuclear medicine that involves the use of radioactive materials (radiopharmaceuticals) to treat various medical conditions, particularly cancer. Unlike conventional external beam radiation therapy, which uses high-energy X-rays or other forms of radiation generated outside the patient's body, nuclear medicine therapeutics uses radiopharmaceuticals that are administered internally and target specific disease sites within the body. Patients receiving nuclear medicine therapies are carefully monitored during and after treatment to assess treatment response and manage potential side effects. Follow-up imaging and tests may be performed to track the progress of the therapy and the patient's condition. Nuclear medicine therapeutics can be tailored to individual patients based on factors such as the type and stage of disease, the patient's overall health, and the response to treatment. This personalized approach aims to maximize treatment efficacy while minimizing side effects.

The global prevalence of cancer continues to increase, driving the demand for effective diagnostic and therapeutic tools. Nuclear medicine plays a crucial role in both cancer diagnosis and treatment, making it a critical component of cancer care. Advances in imaging technologies, such as PET-CT and SPECT-CT, have improved the accuracy of diagnosis and treatment planning. Additionally, the development of more efficient and compact imaging devices has enhanced the accessibility of nuclear medicine. Ongoing clinical trials and research studies have contributed to the expansion of nuclear medicine applications. Positive trial outcomes can lead to the adoption of nuclear medicine therapies in routine clinical practice. The aging global population is more susceptible to chronic diseases, including cancer and cardiovascular conditions, which are often diagnosed and treated using nuclear medicine techniques.

Key Market Drivers

Advancements in Technology

Technological advancements in nuclear medicine therapeutics have been instrumental in improving the accuracy, effectiveness, and safety of diagnostic and treatment procedures. These advancements have expanded the applications of nuclear medicine and enhanced patient care. Hybrid imaging systems, such as PET-CT (Positron Emission Tomography-Computed Tomography) and SPECT-CT (Single-Photon Emission Computed Tomography-Computed Tomography), have become standard in nuclear medicine. These systems combine functional imaging (PET or SPECT) with anatomical imaging (CT) to provide detailed information about both structure and function in a single scan. This allows for more accurate localization of abnormalities and better treatment planning. PET-MRI combines the functional imaging capabilities of PET with the excellent soft tissue contrast of MRI. This technology is particularly valuable in brain imaging and certain oncology applications, offering improved diagnostic accuracy. Research and development efforts have led to the creation of more targeted and effective radiopharmaceuticals. These radiopharmaceuticals can specifically bind to disease markers or receptors, allowing for more precise diagnosis and targeted therapy. Radioligand therapies involve the use of radiopharmaceuticals that target specific receptors on cancer cells. This approach has shown promise in the treatment of various cancers, such as prostate cancer, using agents like Lutetium-177-PSMA. Advances in alpha-particle-emitting radiopharmaceuticals have gained attention for their high energy and short range, making them effective in targeting cancer cells while sparing surrounding healthy tissue. This approach is being explored for certain types of cancer therapy. Theranostics is an emerging field that combines diagnostic and therapeutic capabilities. It involves the use of radiopharmaceuticals for both imaging and therapy. This approach allows for patient-specific treatment planning based on imaging findings.

Dosimetry techniques have improved the ability to estimate and optimize radiation doses delivered to specific target areas while minimizing exposure to healthy tissues. This is crucial for personalized cancer treatment. Automation and robotics have been integrated into nuclear medicine procedures to enhance precision and reduce human error. Automated systems can prepare radiopharmaceuticals, administer treatments, and perform image acquisition. Digital detectors and processing techniques have improved the speed and quality of nuclear medicine imaging. This has led to reduced radiation exposure for patients and faster image acquisition. Quantitative analysis tools have been developed to provide more accurate and reproducible measurements of physiological and molecular parameters. This is particularly valuable for monitoring treatment response and disease progression. Radiomics involves the extraction and analysis of many quantitative image features from medical images. It holds the potential to predict treatment outcomes and provide insights into disease characteristics. AI and machine learning are being applied to nuclear medicine data analysis. AI algorithms can assist in image interpretation, disease diagnosis, treatment planning, and predicting patient outcomes. Advances in radiation protection techniques and equipment ensure the safety of patients and healthcare providers during nuclear medicine procedures. This factor will help in the development of Global Nuclear Medicine Therapeutics Market.

Growing Aging Population

As people age, they are more susceptible to certain age-related diseases, such as cancer, heart disease, and neurodegenerative disorders. Nuclear medicine plays a crucial role in the diagnosis, staging, and treatment of these conditions. Cancer is more common among older adults, and nuclear medicine techniques, such as PET-CT and SPECT-CT, are essential for cancer diagnosis, staging, and monitoring treatment response. Additionally, radiopharmaceuticals are used in cancer therapy, making nuclear medicine a vital component of cancer care for the elderly population. Older adults are at higher risk of cardiovascular diseases, including coronary artery disease and heart failure. Nuclear cardiology techniques, like myocardial perfusion imaging, are used for the assessment of cardiac function and the detection of ischemia, contributing to the management of these conditions. Neurological disorders, such as Alzheimer's disease and Parkinson's disease, become more prevalent with age. Nuclear medicine methods, including PET imaging with specific radiopharmaceuticals, aid in the early diagnosis and monitoring of these conditions. Older adults are at greater risk of osteoporosis and bone fractures. Bone scans using radiopharmaceuticals like technetium-99m are used to assess bone health and identify fractures.

The aging population often requires long-term care and management of chronic conditions. Nuclear medicine provides valuable tools for monitoring disease progression and the effectiveness of treatments over time. Nuclear medicine allows for personalized treatment plans based on an individual's unique health profile and disease characteristics. This approach is especially relevant for older adults who may have multiple comorbidities and varying responses to treatment. Nuclear medicine therapies, such as radioligand therapies, can improve the quality of life for older adults by alleviating symptoms, reducing pain, and managing disease-related complications. The aging population offers a significant pool for clinical research and trials related to nuclear medicine. Studies on the effectiveness of new radiopharmaceuticals and therapeutic approaches often include older adults. The healthcare infrastructure, including the availability of nuclear medicine facilities and expertise, needs to adapt to the increasing healthcare needs of the aging population. This drives investments in healthcare technology and services. Healthcare policy and reimbursement strategies often consider the needs of older adults, which can influence the accessibility and affordability of nuclear medicine services for this demographic. This factor will pace up the demand of Global Nuclear Medicine Therapeutics Market.

Increasing Awareness About Early Diagnosis

Awareness campaigns educate the public about the importance of early detection and diagnosis of various medical conditions, including cancer and cardiovascular diseases. Nuclear medicine techniques like PET-CT and SPECT-CT are highly effective in early disease detection, and increased awareness can lead to more individuals seeking these diagnostic tests. Public awareness initiatives often focus on cancer prevention and screening. When people understand the role of nuclear medicine in cancer diagnosis and staging, they are more likely to undergo regular screenings, leading to early intervention and improved outcomes. Patients who are aware of nuclear medicine options are more likely to discuss these options with their healthcare providers. Informed patients can actively participate in treatment decisions, leading to better-informed choices regarding nuclear medicine therapies. Healthcare providers who are well-informed about nuclear medicine may refer patients for nuclear medicine procedures when appropriate. This awareness among healthcare professionals can lead to increased utilization of nuclear medicine services. Nuclear medicine is continually evolving, with new applications and therapies emerging. Awareness campaigns can help highlight these advancements, leading to greater interest from both patients and healthcare providers.

Health organizations often conduct community outreach programs and events to raise awareness about various healthcare topics, including the benefits of nuclear medicine. These events may include educational sessions and free or discounted screenings. Patient advocacy groups play a crucial role in raising awareness about specific diseases and treatment options. Many of these groups actively promote nuclear medicine as part of their awareness and advocacy efforts. As public perception of nuclear medicine becomes more positive and well-informed, there is a greater acceptance of nuclear medicine as a safe and effective medical specialty. This can lead to increased demand for nuclear medicine services. Greater public awareness can also lead to increased funding for nuclear medicine research. Increased research funding can lead to advancements in technologies, therapies, and diagnostic tools. Public awareness can influence healthcare policies and regulations, leading to improved access to nuclear medicine services and reimbursement for treatments. International awareness campaigns and educational initiatives can help expand the use of nuclear medicine in regions where access to advanced medical technologies may be limited. This factor will accelerate the demand of Global Nuclear Medicine Therapeutics Market.


Download Free Sample Report

Key Market Challenges

Supply Chain and Radioisotope Availability

Nuclear medicine heavily relies on radioisotopes, which are radioactive materials used in imaging and therapy. The production of these radioisotopes can be complex and is often centralized in a few facilities globally. Any disruptions in production or supply can have widespread implications for nuclear medicine services. Many radioisotopes used in nuclear medicine have short half-lives, meaning they decay rapidly. This necessitates just-in-time production and delivery to healthcare facilities. Any delays in production, transportation, or delivery can lead to radioisotope shortages. The global supply chain for radioisotopes can be vulnerable to various factors, such as technical issues in production facilities, regulatory challenges, geopolitical tensions, and transportation disruptions. These vulnerabilities can lead to interruptions in the supply of radioisotopes. The demand for radioisotopes, especially those used in oncology and cardiology, has been steadily increasing. Meeting this growing demand while ensuring a stable supply chain can be a logistical challenge. There are relatively few facilities worldwide that produce medical-grade radioisotopes. Relying on a small number of production centers increases the risk of supply disruptions. The production of radioisotopes often involves the use of nuclear reactors or particle accelerators, which require specialized infrastructure and expertise. Technical challenges or maintenance shutdowns can affect production. Radioisotopes must be transported under strict safety regulations. Delays or disruptions in transportation can impact the timely delivery of radiopharmaceuticals to healthcare facilities.

Competition with Alternative Therapies

Alternative therapies, such as surgery, chemotherapy, radiation therapy, and immunotherapy, may offer varying levels of efficacy for different medical conditions. Healthcare providers must assess the relative effectiveness of nuclear medicine compared to these alternatives. The side effects and tolerability of different treatment options can vary significantly. Nuclear medicine therapies can have side effects, and patients and providers need to consider these effects when making treatment decisions. The cost of nuclear medicine therapies can be high, and this cost can be a barrier to access for some patients. Comparatively, some alternative therapies may be more cost-effective, depending on the specific medical condition and treatment plan. The availability of nuclear medicine services and radiopharmaceuticals can vary by region. Patients may have limited access to nuclear medicine facilities, which can lead them to explore alternative treatments that are more readily available. Patient preferences play a significant role in treatment decisions. Some patients may prefer non-invasive treatments like nuclear medicine, while others may opt for surgical interventions or systemic therapies. Medical guidelines and recommendations may favor certain therapies over others for specific medical conditions. Healthcare providers often adhere to established guidelines when making treatment recommendations.

Key Market Trends

Radiopharmaceutical Production

The growing awareness of nuclear medicine's diagnostic and therapeutic capabilities has led to an increased demand for radiopharmaceuticals. This trend is driven by the rising prevalence of diseases such as cancer and cardiovascular conditions that benefit from nuclear medicine procedures. Ongoing research and development efforts have led to the creation of a diverse range of radiopharmaceuticals, including those for PET, SPECT, and therapeutic applications. This diversification allows for a broader spectrum of medical conditions to be addressed using nuclear medicine. Radiopharmaceuticals can be designed to target specific disease markers or receptors, enabling more precise diagnosis and therapy. Targeted radiopharmaceuticals are a growing area of interest, particularly in oncology. The concept of theranostics, which combines diagnostic and therapeutic capabilities using the same radiopharmaceutical, has gained traction. Theranostic approaches allow for personalized treatment planning based on diagnostic imaging findings. Improvements in radioisotope production methods have contributed to a more reliable and efficient supply of radiopharmaceuticals. Cyclotron and generator technologies have advanced to support increased production capacity. Efforts have been made to reduce the production time for radiopharmaceuticals with short half-lives. This is crucial for ensuring timely access to these materials.

Segmental Insights

Type Insights

In 2022, the Global Nuclear Medicine Therapeutics Market dominated by Beta Emitters segment and is predicted to continue expanding over the coming years.  Beta emitters offer a versatile range of radiation energies and penetration depths, making them suitable for targeting different types of tumours and cancerous tissues. This versatility allows for the treatment of a wide variety of cancers. Beta-emitting radiopharmaceuticals, including iodine-131 and lutetium-177, are readily available and have well-established production processes. This availability facilitates their use in clinical practice. Many beta-emitting isotopes have longer half-lives compared to alpha emitters, which means they can be transported and used in medical facilities with less urgency. This longer half-life allows for more flexibility in logistics. The use of beta emitters in nuclear medicine therapy is generally well-accepted by patients due to their established track record and effectiveness in treating cancer.

Application Insights

In 2022, the Global Nuclear Medicine Therapeutics Market largest share was dominated by oncology segment in the forecast period and is predicted to continue expanding over the coming years. Cancer is a leading cause of mortality and a significant public health concern worldwide. The high prevalence of various types of cancer, including lung, breast, prostate, and colorectal cancer, drives the demand for effective diagnostic and therapeutic tools, including nuclear medicine techniques. Nuclear medicine plays a crucial role in the diagnosis and staging of cancer. Techniques like positron emission tomography (PET) and single-photon emission computed tomography (SPECT) with radiopharmaceuticals are used to detect tumours, assess their size, and spread, and determine treatment strategies. Accurate diagnosis is vital for effective cancer management. Ongoing research and development have led to the creation of advanced radiopharmaceuticals specifically designed for cancer imaging and therapy. These radiopharmaceuticals offer improved accuracy and effectiveness in cancer diagnosis and treatment.


Download Free Sample Report

Regional Insights

The North America region dominates the Global Nuclear Medicine Therapeutics Market in 2022. North America, particularly the United States and Canada, boasts a highly developed and advanced healthcare infrastructure. This includes a network of well-equipped hospitals, research institutions, and medical facilities that are well-suited for the practice of nuclear medicine. The United States has one of the highest healthcare expenditures in the world. This substantial investment in healthcare infrastructure and research and development provides a conducive environment for the growth of the nuclear medicine therapeutics market. The region is home to many leading pharmaceutical and biotechnology companies, academic research centers, and healthcare organizations. These entities invest significantly in research and development, leading to the development and commercialization of innovative nuclear medicine therapies.

Recent Developments

  • In February 2023, according to the Research Cooperation Agreement published in February 2021, Telix Pharmaceuticals Limited has reported the successful completion of its cooperative research project with Heidelberg University Hospital (UKHD). Using the beta-emitting isotope rhenium-188, the goal of this study was to develop and verify a generator-based theranostic drug for urologic cancer that targets PSMA. A targeted agent that can be coupled with a true-theranostic pair of radioisotopes—99mTc (technetium-99m) for imaging and 188Re for therapeutic purposes—makes up the technology platform. Due to its strong energy output over a 16.9-hour half-life and its capability to be consistently supplied at the point of care through a generator, 188Re is seen as an appealing alternative for radiopharmaceutical therapy applications.
  • In September 2022, an oral presentation of the Phase 1 data from the ReSPECT-GBM Phase 1/2a dose escalation clinical trial evaluating the Company's lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in recurrent glioblastoma (GBM) at the European Society for Medical Oncology (ESMO) Congress 20 was made today by Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing novel, targeted radiotherapeutics for uncommon. A clinical-stage pharmaceutical firm called Plus Therapeutics, Inc. is dedicated to the creation, production, and distribution of sophisticated and cutting-edge therapies for people suffering from cancer and other serious illnesses. Our unique nanotechnology platform's current focus is on improving medicine delivery using cutting-edge liposomal encapsulation technology.

Key Market Players

  • Actinium Pharmaceutical Inc.
  • Alpha Tau Medical Ltd
  • Bayer AG
  • Fusion Pharmaceuticals Inc.
  • IBA Radiopharma Solutions
  • RadioMedix Inc.
  • Telix Pharmaceuticals Ltd
  • NTP Radioisotopes Pty Ltd.
  • Bracco SpA
  • Cardinal Health Inc.
  • Nordion Inc. (Sotera Health Company)
  • Triad Isotopes Inc. (Jubilant Life Sciences)

 

By Type

By Application

By Region

By Region
  • Alpha Emitters
  • Beta Emitters
  • Brachytherapy
  • Oncology
  • Cardiology
  • Thyroid
  • Other Applications
  • North America
  • Asia-Pacific
  • Europe
  • South America
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • Kuwait
  • Bahrain
  • Rest of Middle East

 

Report Scope:

In this report, the Global Nuclear Medicine Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  •  Nuclear Medicine Therapeutics Market, By Type:

o   Alpha Emitters

§  Radium-223 (RA-223) & Alpharadin

§  Actinium-225 (AC-225)

§  Lead-212 (PB-212)/Bismuth-212 (BI-212)

§  Other Alpha Emitters

o   Beta Emitters

§  Iodine-131 (I-131)

§  Yttrium-90 (Y-90)

§  Other Beta Emitters

o   Brachytherapy

§  Cesium-131

§  Iodine-125

§  Other Brachytherapies

  •  Nuclear Medicine Therapeutics Market, By Application:

o   Oncology

o   Cardiology

o   Thyroid

o   Other Applications

  • Global Nuclear Medicine Therapeutics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nuclear Medicine Therapeutics Market.

Available Customizations:

Global Nuclear Medicine Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Nuclear Medicine Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

 1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Nuclear Medicine Therapeutics Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Type (Alpha Emitters, Beta Emitters, and Brachytherapy)

5.2.2.    By Application (Oncology, Cardiology, Thyroid, and Other Applications)

5.2.3.    By Region

5.2.4.    By Company (2022)

5.3.  Market Map

6.    Asia Pacific Nuclear Medicine Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Type

6.2.2.    By Application

6.2.3.    By Country

6.3.  Asia Pacific: Country Analysis

6.3.1.    China Nuclear Medicine Therapeutics Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Type

6.3.1.2.2.           By Application

6.3.2.    India Nuclear Medicine Therapeutics Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Type

6.3.2.2.2.           By Application

6.3.3.    Australia Nuclear Medicine Therapeutics Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Type

6.3.3.2.2.           By Application

6.3.4.    Japan Nuclear Medicine Therapeutics Market Outlook

6.3.4.1.        Market Size & Forecast

6.3.4.1.1.           By Value

6.3.4.2.        Market Share & Forecast

6.3.4.2.1.           By Type

6.3.4.2.2.           By Application

6.3.5.    South Korea Nuclear Medicine Therapeutics Market Outlook

6.3.5.1.        Market Size & Forecast

6.3.5.1.1.           By Value

6.3.5.2.        Market Share & Forecast

6.3.5.2.1.           By Type

6.3.5.2.2.           By Application

7.    Europe Nuclear Medicine Therapeutics Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Type

7.2.2.    By Application

7.2.3.    By Country

7.3.  Europe: Country Analysis

7.3.1.    France Nuclear Medicine Therapeutics Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Type

7.3.1.2.2.           By Application

7.3.2.    Germany Nuclear Medicine Therapeutics Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Type

7.3.2.2.2.           By Application

7.3.3.    Spain Nuclear Medicine Therapeutics Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Type

7.3.3.2.2.           By Application

7.3.4.    Italy Nuclear Medicine Therapeutics Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Type

7.3.4.2.2.           By Application

7.3.5.    United Kingdom Nuclear Medicine Therapeutics Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Type

7.3.5.2.2.           By Application

8.    North America Nuclear Medicine Therapeutics Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Type

8.2.2.    By Application

8.2.3.    By Country

8.3.  North America: Country Analysis

8.3.1.    United States Nuclear Medicine Therapeutics Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Type

8.3.1.2.2.           By Application

8.3.2.    Mexico Nuclear Medicine Therapeutics Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Type

8.3.2.2.2.           By Application

8.3.3.    Canada Nuclear Medicine Therapeutics Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Type

8.3.3.2.2.           By Application

9.    South America Nuclear Medicine Therapeutics Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Type

9.2.2.    By Application

9.2.3.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil Nuclear Medicine Therapeutics Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Type

9.3.1.2.2.           By Application

9.3.2.    Argentina Nuclear Medicine Therapeutics Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Type

9.3.2.2.2.           By Application

9.3.3.    Colombia Nuclear Medicine Therapeutics Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Type

9.3.3.2.2.           By Application

10. Middle East and Africa Nuclear Medicine Therapeutics Market Outlook

10.1.             Market Size & Forecast

10.1.1. By Value

10.2.             Market Share & Forecast

10.2.1. By Type

10.2.2. By Application

10.2.3. By Country

10.3.             MEA: Country Analysis

10.3.1. South Africa Nuclear Medicine Therapeutics Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Type

10.3.1.2.2.         By Application

10.3.2. Saudi Arabia Nuclear Medicine Therapeutics Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Type

10.3.2.2.2.         By Application

10.3.3. UAE Nuclear Medicine Therapeutics Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Type

10.3.3.2.2.         By Application

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Recent Developments

12.2.             Product Launches

12.3.             Mergers & Acquisitions

13. Global Nuclear Medicine Therapeutics Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1.             Competition in the Industry

14.2.             Potential of New Entrants

14.3.             Power of Suppliers

14.4.             Power of Customers

14.5.             Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1.   Actinium Pharmaceutical Inc.

16.1.1.     Business Overview

16.1.2.     Company Snapshot

16.1.3.     Products & Services

16.1.4.     Financials (In case of listed companies)

16.1.5.     Recent Developments

16.1.6.     SWOT Analysis

16.2.   Alpha Tau Medical Ltd

16.2.1.     Business Overview

16.2.2.     Company Snapshot

16.2.3.     Products & Services

16.2.4.     Financials (In case of listed companies)

16.2.5.     Recent Developments

16.2.6.     SWOT Analysis

16.3.   Bayer AG

16.3.1.     Business Overview

16.3.2.     Company Snapshot

16.3.3.     Products & Services

16.3.4.     Financials (In case of listed companies)

16.3.5.     Recent Developments

16.3.6.     SWOT Analysis

16.4.   Fusion Pharmaceuticals Inc.

16.4.1.     Business Overview

16.4.2.     Company Snapshot

16.4.3.     Products & Services

16.4.4.     Financials (In case of listed companies)

16.4.5.     Recent Developments

16.4.6.     SWOT Analysis

16.5.   IBA Radiopharma Solutions

16.5.1.     Business Overview

16.5.2.     Company Snapshot

16.5.3.     Products & Services

16.5.4.     Financials (In case of listed companies)

16.5.5.     Recent Developments

16.5.6.     SWOT Analysis

16.6.   RadioMedix Inc.

16.6.1.     Business Overview

16.6.2.     Company Snapshot

16.6.3.     Products & Services

16.6.4.     Financials (In case of listed companies)

16.6.5.     Recent Developments

16.6.6.     SWOT Analysis

16.7.   Telix Pharmaceuticals Ltd

16.7.1.     Business Overview

16.7.2.     Company Snapshot

16.7.3.     Products & Services

16.7.4.     Financials (In case of listed companies)

16.7.5.     Recent Developments

16.7.6.     SWOT Analysis

16.8.   NTP Radioisotopes Pty Ltd.

16.8.1.     Business Overview

16.8.2.     Company Snapshot

16.8.3.     Products & Services

16.8.4.     Financials (In case of listed companies)

16.8.5.     Recent Developments

16.8.6.     SWOT Analysis

16.9.   Bracco SpA

16.9.1.     Business Overview

16.9.2.     Company Snapshot

16.9.3.     Products & Services

16.9.4.     Financials (In case of listed companies)

16.9.5.     Recent Developments

16.9.6.     SWOT Analysis

16.10.Cardinal Health Inc.

16.10.1.                  Business Overview

16.10.2.                  Company Snapshot

16.10.3.                  Products & Services

16.10.4.                  Financials (In case of listed companies)

16.10.5.                  Recent Developments

16.10.6.                  SWOT Analysis

16.11.Nordion Inc. (Sotera Health Company)

16.11.1.                  Business Overview

16.11.2.                  Company Snapshot

16.11.3.                  Products & Services

16.11.4.                  Financials (In case of listed companies)

16.11.5.                  Recent Developments

16.11.6.                  SWOT Analysis

16.12.Triad Isotopes Inc. (Jubilant Life Sciences)

16.12.1.                  Business Overview

16.12.2.                  Company Snapshot

16.12.3.                  Products & Services

16.12.4.                  Financials (In case of listed companies)

16.12.5.                  Recent Developments

16.12.6.                  SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Nuclear Medicine Therapeutics Market was estimated to be USD 985.80 million in 2022.

down-arrow

Telix Pharmaceuticals Ltd, NTP Radioisotopes Pty Ltd., Bracco SpA are some of the key players operating in the Nuclear Medicine Therapeutics Market.

down-arrow

Ensuring the safety of patients, healthcare workers, and the environment is paramount in nuclear medicine.

down-arrow

The trend towards personalized medicine has extended to nuclear medicine therapeutics.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Nuclear Medicine Therapeutics Market to grow with a CAGR of 9.60%

Oct, 2023

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Nuclear Medicine Therapeutics Market.

Why Choose Us